Medical Device Weekly Highlights [April 14–20, 2026]: JunDe MedTech Files IPO Prospectus

Recently, Shenzhen Dongbi Technology Data Co., Ltd. and Shenzhen Zhongke Micro-Light Medical Equipment Technology Co., Ltd. officially reached a cooperation agreement and signed a contract. Both parties announced that they will jointly develop the "Global High-Quality Corpus of Scientific and Technological Achievements in the Cardiovascular Field" based on artificial intelligence and big data technologies. This initiative aims to accelerate the clinical transformation and intelligent application of cardiovascular research achievements and promote innovation in medical AI technology. The collaboration deeply integrates Dongbi Technology Data's data processing expertise with Micro-Light Medical’s clinical data resources, aiming to build a structured corpus for the global cardiovascular vertical field, resolve the "data silo" issue in medical AI, and enhance the efficiency of precision diagnosis, treatment, and scientific research transformation.

Recently, the Central Commission for Discipline Inspection (CCDI) once again named equipment and device procurement as a focus, with anti-corruption efforts advancing across the entire medical industry chain. The CCDI's official website published an article by Qu Xiaoli, head of the CCDI’s disciplinary inspection team stationed at the National Health Commission, titled "Deepening the Rectification of Misconduct and Corruption Close to the People." The article emphasized continued scrutiny of the "key few" and critical positions within supervised units, focusing on key areas and critical links such as drug procurement, high-value medical consumables, medical devices, project bidding, and the management of research funding. It stressed the need to severely punish "petty corruption," correct deep-rooted problems, and resolutely prevent a resurgence of corruption and misconduct in the pharmaceuticals sector. High-value consumables and medical devices are expensive, and individuals with control over procurement decisions can easily fall into the trap of corruption. Recently, several hospital directors have been arrested for manipulating equipment procurement.

Recently, according to statistics from the National Health Commission's Stroke Center, as of mid-March 2025, China has cumulatively built approximately 2,300 stroke centers nationwide, including more than 710 tertiary hospital stroke centers and about 2,570 secondary hospital stroke centers, with stroke center coverage in districts and counties exceeding 50%. The normalization of centralized procurement for neurointerventional products has generally covered the entire product lines of various manufacturers, and the overall impact has largely come to an end. In the "3+N" alliance centralized procurement led by Hebei in early 2024 in the Beijing-Tianjin-Hebei region, MicroPort Brain Science’s APOLLO™ intracranial stent became the selected domestically produced intracranial stent, further expanding its market share; NUMEN® coils, leveraging the centralized procurement, were newly introduced into approximately 520 hospitals in 2024, with cumulative commercial clinical applications in nearly 1,450 hospitals.

Recently, the Evaluation Center of Jiangsu Provincial Medical Products Administration has taken the capacity building of evaluation and inspection sub-centers as a key measure to systematically promote team capability enhancement, institutional mechanism innovation, and collaborative efficiency in evaluation. This aims to comprehensively drive the high-quality development of medical device evaluation work across China. Focusing on the unification of systems and standards, a standardized evaluation system has been established. The "Control Procedure for Evaluation of Registration Materials of Category II Medical Devices Authorized to Sub-centers" was compiled, specifying process management and time limit requirements. Addressing the evaluation of complex products, technical evaluation guidelines for three specific products have been developed, clarifying operational procedures, judgment rules, and solutions for common technical issues in evaluations to reduce product understanding discrepancies and unify evaluation standards. The Evaluation Center regularly conducts quality supervision and inspection of medical device evaluation cases at nine authorized evaluation and inspection sub-centers. Monthly sampling is performed, and senior evaluators organize quality audits, recording and providing feedback on identified issues to each sub-center.

Recently, according to "Beijing Yizhuang" news, the series of national standards for technical requirements of humanoid robots has been officially approved for project initiation. This is the national standard in China's humanoid robot field, involving multiple technical requirements such as environmental perception, decision-making planning, motion control, and operational tasks. Enterprises from Beijing Economic-Technological Development Area (Beijing Yizhuang) are deeply involved, with Beijing Humanoid Robot Innovation Center Co., Ltd. and UBTECH Robotics, which has its humanoid robot headquarters in Beijing Yizhuang, being co-initiators of this series of national standards. The Beijing Humanoid Robot Innovation Center is the main contributor to the series of national standards for humanoid robot technical requirements, leading the drafting of motion control technical requirements, and jointly leading operational task technical requirements, decision-making planning technical requirements, and environmental perception technical requirements. In this series of national standards, UBTECH Robotics took the lead in formulating the operational task technical requirements, standardizing key aspects such as dexterous operation, legged mobile operations, dual-arm operation, long sequence execution, multi-machine collaboration, operational obstacle avoidance, and endurance.

Recently, the General Office of Henan Provincial People's Government issued the "Henan Province Medical Instrument and Equipment Industrial Park Layout and Construction Plan," proposing to focus on the development of seven medical instrument and equipment industrial parks across the province. These include the Aviation Port Area International Medical Instrument and Equipment Industrial Park, Zhengzhou Economic Development Zone High-end Medical Instrument and Equipment Industrial Park, Zhengzhou High-tech Zone Digital Medical Instrument and Equipment Industrial Park, Xinxiang Specialty Treatment Equipment and High-value Medical Consumables Industrial Park, Anyang Intelligent Rehabilitation Medical Instrument and Equipment Industrial Park, Shangqiu Smart Medical and Rehabilitation Equipment Industrial Park, and Xinyang High-end Medical Equipment Manufacturing Industrial Park. By 2027, the plan aims to form two industrial parks with a scale exceeding 10 billion yuan each, attract more than 10 leading domestic and international medical instrument and equipment enterprises, cultivate over a hundred specialized and innovative medical instrument and equipment companies as well as hard tech startups, achieve approval for more than five innovative medical instruments and equipment, and drive the overall scale of Henan's medical instrument and equipment industry to surpass 70 billion yuan.

Notice on the Renewal of the Third Procurement Year Contract for Volume-based Procurement of Orthopedic Spinal Medical Devices in Hainan ProvinceIn order to thoroughly implement the decisions and arrangements of the CPC Central Committee and the State Council, and to continuously promote the price governance of medical consumables, the Hainan Provincial Medical Insurance Bureau announces matters related to the renewal of the third procurement year contract during the agreement period for volume-based procurement of orthopedic spinal medical devices. The procurement cycle for volume-based procurement of orthopedic spinal consumables is three years, starting from the actual execution date of Hainan Province’s selection results on April 25, 2023. The second annual procurement period will end on April 25, 2025. The Hainan Provincial Public Resources Trading Service Center should organize all medical institutions, production enterprises, and their designated distribution companies to timely complete the signing of the volume-based purchase and sale contracts for the third procurement year of orthopedic spinal medical devices on the provincial pharmaceutical centralized procurement platform, ensuring the implementation of the third procurement year starting from April 25, 2025.

In order to thoroughly implement the spirit of the Third Plenary Session of the 20th Central Committee of the Communist Party of China, and to implement the requirements of the "Opinions of the General Office of the State Council on Comprehensively Deepening the Reform of Drug and Medical Device Supervision to Promote the High-Quality Development of the Pharmaceutical Industry" (Guo Ban Fa [2024] No. 53), further optimize the review of innovations and the priority approval process, strengthen communication between applicants and review experts, enhance technical guidance for the research and development and registration of innovative medical devices and priority approval medical devices, and guide applicants in designing and developing innovative medical devices that meet clinical needs, based on the "Announcement of the National Medical Products Administration on the Release of the Special Review Procedures for Innovative Medical Devices" (No. 83 [2018]) and the "Announcement of the China Food and Drug Administration on the Release of the Priority Approval Procedures for Medical Devices" (No. 168 [2016]), the Center for Medical Device Evaluation has formulated the "Detailed Implementation Rules for the Review of Applications for Special Review of Innovative Medical Devices by the Center for Medical Device Evaluation" and the "Detailed Implementation Rules for the Examination of Priority Approval Applications for Medical Devices by the Center for Medical Device Evaluation", which are hereby released.

According to statistics from the National Health Commission's Stroke Center, as of mid-March 2025, China has cumulatively established approximately 2,300 stroke centers, including over 710 tertiary hospital stroke centers and about 2,570 secondary hospital stroke centers, with stroke center coverage in districts and counties exceeding 50%. The normalization of centralized procurement for neurointerventional products has largely covered the entire product lines of various manufacturers, and the overall impact has generally come to an end. In the "3+N" alliance centralized procurement led by Hebei in early 2024, which includes Beijing and Tianjin, MicroPort NeuroTech's APOLLO™ intracranial stent was selected as a domestically produced intracranial stent, further expanding its market share; NUMEN® coils, leveraging the centralized procurement, were newly introduced into approximately 520 hospitals in 2024, with cumulative commercial clinical applications in nearly 1,450 hospitals.